William Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses treatment of chronic lymphocytic leukemia (CLL) in young and elderly patients.
William Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses treatment of chronic lymphocytic leukemia (CLL) in young and elderly patients.
Older patients with CLL tend to have lower tolerance of some chemotherapies than younger patients because they have more illnesses or are taking more medications.
Wierda says that recent trials show promising results of more effective treatments than chemotherapy for CLL.
Wierda adds that patient age will become less relevant as a prognostic factor as new therapies emerge.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.